Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy International Prognostic Factors Study Group Journal of Clinical Oncology 28 (33), 4906-4911, 2010 | 300 | 2010 |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 266 | 2017 |
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma GL Ceresoli, PA Zucali, F De Vincenzo, L Gianoncelli, M Simonelli, ... Lung cancer 72 (1), 73-77, 2011 | 170 | 2011 |
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy PA Zucali, T De Pas, G Palmieri, A Favaretto, A Chella, M Tiseo, M Caruso, ... Journal of Clinical Oncology 36 (4), 342-349, 2018 | 144 | 2018 |
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience F Pessina, P Navarria, L Cozzi, AM Ascolese, M Simonelli, A Santoro, ... Journal of neuro-oncology 135, 129-139, 2017 | 143 | 2017 |
Advances in the biology of malignant pleural mesothelioma PA Zucali, GL Ceresoli, F De Vincenzo, M Simonelli, E Lorenzi, ... Cancer treatment reviews 37 (7), 543-558, 2011 | 142 | 2011 |
Phase II study of asparagine-glycine-arginine–human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural … V Gregorc, PA Zucali, A Santoro, GL Ceresoli, G Citterio, TM De Pas, ... Journal of Clinical Oncology 28 (15), 2604-2611, 2010 | 142 | 2010 |
Neutrophils in gliomas M Massara, P Persico, O Bonavita, V Mollica Poeta, M Locati, M Simonelli, ... Frontiers in immunology 8, 1349, 2017 | 129 | 2017 |
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey PA Zucali, M Simonelli, G Michetti, M Tiseo, GL Ceresoli, E Collovà, ... Lung Cancer 75 (3), 360-367, 2012 | 122 | 2012 |
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin PA Zucali, E Giovannetti, A Destro, M Mencoboni, GL Ceresoli, ... Clinical Cancer Research 17 (8), 2581-2590, 2011 | 120 | 2011 |
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial DA Reardon, TM Kim, JS Frenel, M Simonelli, J Lopez, DS Subramaniam, ... Cancer 127 (10), 1620-1629, 2021 | 86 | 2021 |
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis A Santoro, M Simonelli, C Rodriguez-Lope, P Zucali, LH Camacho, ... British journal of cancer 108 (1), 21-24, 2013 | 86 | 2013 |
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma E Lopci, M Riva, L Olivari, F Raneri, R Soffietti, A Piccardo, A Bizzi, ... European journal of nuclear medicine and molecular imaging 44, 1155-1164, 2017 | 85 | 2017 |
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas M Rossi, L Gay, F Ambrogi, M Conti Nibali, T Sciortino, G Puglisi, ... Neuro-oncology 23 (5), 812-826, 2021 | 84 | 2021 |
Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas PA Zucali, I Petrini, E Lorenzi, M Merino, L Cao, L Di Tommaso, HS Lee, ... Cancer 116 (20), 4686-4695, 2010 | 78 | 2010 |
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma PA Zucali, M Perrino, E Lorenzi, GL Ceresoli, F De Vincenzo, M Simonelli, ... Lung Cancer 84 (3), 265-270, 2014 | 72 | 2014 |
Role of myeloid cells in the immunosuppressive microenvironment in gliomas CV Locarno, M Simonelli, C Carenza, A Capucetti, E Stanzani, E Lorenzi, ... Immunobiology 225 (1), 151853, 2020 | 71 | 2020 |
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome M Rossi, F Ambrogi, L Gay, M Gallucci, MC Nibali, A Leonetti, G Puglisi, ... Journal of Neurosurgery 132 (6), 1692-1705, 2019 | 62 | 2019 |
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors I Puzanov, J Sosman, A Santoro, MW Saif, L Goff, GK Dy, P Zucali, ... Investigational New Drugs 33, 159-168, 2015 | 58 | 2015 |
CAG mutation effect on rate of progression in Huntington's disease F Squitieri, M Cannella, M Simonelli Neurological Sciences 23, s107-s108, 2002 | 57 | 2002 |